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• Genistein reduced the development of brain edema in a model of brain injury.
• Increase of ICP was suppressed by administration of genistein in a model of brain injury.
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Brain edemaThe concerns about negative consequences of estrogen therapy have led to introduce other strategies to obtain
estrogen's beneﬁts in the brain. The present study tests the hypothesis that a major isoﬂavone of soy; genistein
with estrogen-like activity can be neuroprotective in traumatic brain injury (TBI). ThemaleWistar rats were ran-
domly divided to four groups: sham, TBI, vehicle and genistein. The TBI was induced by Marmarou method. The
brain edema and the disruption of blood–brain-barrier (BBB)were evaluated 48 h post-TBI. Genistein (15mg/kg)
or dimethyl sulfoxide (DMSO)was injected i.p., twice after TBI. The intracranial pressure (ICP), themotor perfor-
mance, and the beam-walk task (WB) were determined before trauma, on trauma day (D0), and ﬁrst (D1) and
second (D2) days post-TBI. Genistein inhibited a development of brain edema and a BBB permeability in TBI
animals. An increase of ICP and a defect in motor and WB performance were showed following TBI, in all times
evaluated. An increase of ICP induced by TBI was suppressed by genistein on D1 and D2 times. Genistein
improved a motor disorder induced by TBI, on D1 and D2 times. Also an increase of traversal time in WB task
was suppressed by genistein in TBI animals, on D1 and D2 times. The results of this study demonstrated that
genistein can be neuroprotective in TBI. Genistein inhibited the disruption of BBB, the brain edema and the
increase of ICP, and the disturbance of neurobehavioral performance in TBI.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Traumatic brain injury (TBI) is the third most common cause of
death in the world [1]. TBI accounts for 52% of the trauma-induced
deaths and is therefore a leading cause of death among trauma patients
[2]. On average, 39% of patients with a severe TBI die from their injury
[3]. In Iran, road-trafﬁc crashes, which are a main source of brain inju-
ries, cause disability to more than 300,000 persons each year [4].
Traumatic brain injury (TBI) immediately causes both the primary
damage and the secondary damage. The primary damage is induced
due to a direct mechanical damage of the brain, resulting in the imme-
diate and irreversible neuronal death [5]. The secondary damage is
evolved by a large number of cellular, molecular, and biochemical
cascades, resulting in the avoidable neuronal death for hours after TBI.One such cascade is an inﬂammatory response in an injured brain [6].
Applying treatment strategies before an occurrence of permanent neu-
ronal damage in TBI is very important.
Previous studies have demonstrated an anti-inﬂammatory and neu-
roprotective effect of estrogen in TBI [7–9]. Soy phytoestrogens have
been introduced as an alternative to hormone replacement therapy,
due to the deleterious effects of estrogen [10]. Soy isoﬂavones, such as
genistein and daidzein have phytoestrogen properties [11,12] and can
act as an estrogen receptor modulator or act through a non-estrogen
receptor pathway [13].
Both ovariectomized female and male rats with a soy diet have
shown a signiﬁcant reduction in infarct volume, neurological defect,
and apoptosis following cerebral ischemia [14,15]. Genistein has similar
protective effects in both sexes in cerebral ischemia [16,17]. Genistein is
also found in lupine (Lupinus), alfalfa (Medicago sativa), chickpea, and
some legumes (Leguminosae) [18,19]. Genistein has anti-inﬂammatory
and antioxidant properties [20]. Our recent study showed that a soy
Table 1
Motor score scale of neurologic outcome.
Variable Score
Motor
function
Normal movement 8
Mildly drowsy with spontaneous, purposeful movements 7
Lethargic, unable to stand, but maintains sternal recumbency 6
Lethargic, withdraws to pinch, and lifts head with attention to
visual stimuli; no sternal recumbency
5
Withdraws or pedals to pinch 4
Spontaneous pedaling 3
Extensor posturing (spontaneous or to stimuli) 2
Flaccid to stimuli 1
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and the increase of intracranial pressure (ICP), and the improvement of
neurologic performance, in TBI animals [21].
Genistein at low dose reduces the neuronal apoptosis and damage
induced by thapsigargin [25], oxidative stress [22], and glutamate
excitotoxicity [23]. But genistein at high dose may induce a neuronal
apoptosis [24]. In addition, chronic administration of genistein reduces
a brain lesion after experimental stroke and delays the onset of dis-
ability and mortality in a model of amyotrophic lateral sclerosis [19].
However chronic treatment of genistein at high doses may induce cyto-
toxicity and apoptosis in a rat brain [25].
The neuroprotective effect of estrogen in TBI animals has been sug-
gested in our previous studies [7–9], and our recent study demonstrated
that a soy diet can be neuropreventive in TBI [21], and also the estrogen-
like activity of soy isoﬂavones has been indicated [11,12]. Therefore in
this research, the neuroprotective effect of genistein, as an isoﬂavone
of soy, in diffuse and severe experimental TBI was assessed. With this
aim, we tested the effect of genistein on the brain edema by measuring
brain water content, the BBB permeability by measuring brain leakage
of Evans blue, the ICP by digital recording, and the neurobehavioral out-
come by evaluating motor and vestibulomotor function.
2. Materials and methods
2.1. Animals and animal groups
The study was executed in accordance with a protocol approved by
an ethical committee (No. EC/KNRC/92–23) in Kerman University of
Medical Sciences, in accordance with internationally approved guide-
lines for the animal use and care, as indicated in the European commu-
nity guidelines (EUDirective of 2010; 010/63/EU) or US guidelines (NIH
publication #85-23, revised in 1985).
The male Wistar rats, were purchased just after weaning (3-weeks
after birth), and received a soy-free diet [21] to avoid interference due
to soy. Animals were housed in a light (on 7:00 a.m. to 7:00 p.m.) and
a temperature (21 ± 1 °C) controlled environment with a food and
water available ad libitum and allowed to grow for 15–17 additional
weeks.
Rats were then randomly divided to sham (control), TBI, vehicle of
genistein (Veh) and genistein (Gen) groups (n = 12 in each group).
Six rats in each group were used for determining BBB permeability
and other six rats for recording ICP and evaluating neurobehavioral
outcome.
Genistein (Sigma, USA) (15 mg/kg) [26] was dissolved in dimethyl
sulfoxide (DMSO) and injected through intraperitoneal, once 30 min
and again 24 h [26] after TBI in the genistein group. DMSOwas injected
than genistein in the vehicle group.
2.2. Surgery (induction of TBI)
All animals were intubated before surgery. In all groups except sham
group, diffuse TBI was induced byMarmaroumethod using a TBI induc-
tion device (made by Dept. of Physiology and Pharmacology, Kerman
University of Medical Sciences) in animals anesthetized with ketamine
(60 mg/kg) and xylazine (10 mg/kg). TBI was induced as we have pre-
viously described in detail [7]. Brieﬂy, a severe TBI was induced by fall-
ing a weight 450 g, from a 2 m height onto a metal disk (stainless steel,
10mm in diameter, 3 mm thick) attached to the animal's skull. After an
induction of TBI, the rats were connected to a respiratory pump (TSA
animal respiratory compact, Germany). In the sham group, all stages
of TBI induction were performed except falling weight on the skull.
2.3. Determination of brain edema
The brain edemawas determined bymeasuring brain water content
as we have previously described in detail [7]. Brieﬂy, the brain ofanesthetized animals was removed 48 h after TBI, and the brain sample
was weighed (wet weight). The brain sample was placed in an incuba-
tor (Memmert, Germany) at 60 °C for 72 h, and then was reweighed
(dryweight). The percentage ofwater in each samplewas then calculat-
ed using a formula; (100 × [(wet weight− dry weight) / wet weight]).2.4. Determination of BBB permeability
Blood–brain-barrier (BBB) disruptionwas determined bymeasuring
a brain leakage of Evans blue (EB) dye injected and using a spectropho-
tometer aswe have previously described in detail [27]. Brieﬂy, 48 h after
trauma, 20mg/kg Evans blue dye 2% (1ml/kg) was injected via a jug-
ular vein, under an anesthesia to 50mg/kg thiopental. One hour after
injection, the thorax was opened and descending aorta was clipped.
Then, an isotonic saline solution was infused into the left ventricle
for 20min, simultaneouswith bilaterally cutting jugular vein to remove
intravascular Evans blue dye. Next, the brain was removed and
weighed, followed by homogenization. Then, it was placed in a solution
containing 6 ml of sodium sulfate 1% + 14 ml acetone on a shaker for
24 h. In the next step, 1 ml of the supernatant liquid and 1ml of trichlo-
roacetic acid were mixed and then were centrifuged at 2000 cycle/min
for 10 min. Then, an Evans blue absorbance of the supernatant liquid
was measured at 620 nm by a spectrophotometer (Pharmacia Biotech,
Germany). The amount of dye leakage was quantiﬁed as micrograms
per gram brain tissue.2.5. Measurement of ICP
The animal head was ﬁxed in a stereotaxic instrument, as the head
was located at a midsagittal plane, and the anterior–posterior point
was placed at about a midpoint between the occipital crest and the
lambda suture. A 20-gauge needle connected to a pressure transducer
through a polyethylene short tube,was connected to a recording system
(AD Instruments, Australia) and inserted into the cisternamagna. There
was an initial increase and then a sudden decrease of resistance during
insertion of a needle, due to the needle insertion to dura mater and
cistern magna respectively [28]. The ICP of all groups was recorded be-
fore trauma, on trauma day (D0), and ﬁrst (D1) and second (D2) days
post-TBI.2.6. Neurobehavioral performance
2.6.1. Evaluation of motor function
As we described previously, the motor function was evaluated ac-
cording to a motor score of veterinary coma scale (VCS) and expressed
as a range from 1 to 8 [21,29] (Table 1). A higher score indicates a better
function, and a lower one indicates a worse function. The assessment of
motor functionwas performed by an experienced person blinded to the
experimental condition, before trauma, and on D0, D1 and D2 times of
post-TBI.
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The task of beam-walk (BW)was used for evaluating the ﬁner com-
ponents of vestibulomotor function and coordination. Themodiﬁed BW
task was devised by Feeney and colleagues [30], consisting of training
the animals using a negative-reinforcement paradigm to escape a bright
light and a white noise by traversing an elevated narrow beam
(2.5 × 100 cm) and entering a dark goal box placed on the opposite
end (using an instrument made by the Dept. of Physiology, Kerman
University of Medical Sciences). A task of BWwas assessed by recording
the time traversed to a beam as well as the distance traversed. The
scoring criterion for distance traversed is based on a rating scale from
0 to 5, where 0 indicates inability to move from a starting point, 1–4
correspond to the traveled segments of 20, 40, 60, or 80 cm from a
starting point, respectively, and 5 indicates a traveled entire length of
the beam (100 cm). Animals were trained prior to TBI or sham surgery
(i.e., traverse entire length of the beam under 5 s). “A distance traveled
in the task of BWwaswhen rats fell from the beamon a foamor traveled
the entire length of the beam and arrived to the dark box without the
time limitation.”
The task of BWwas evaluated before trauma, and on D0, D1 and D2
times of post-TBI consisting of three trials for any time evaluated. Data
for each time were a mean of three trials. The results were obtained
using a camera and a software (video tracking, Borjesanat Company,
Tehran, Iran) by an experienced person blinded for the experimental
condition.
2.7. Statistical analysis
Data were expressed as mean ± SEM. The normality of data was
checked by using the Shapiro–Wilk's W test. Because of interaction
between the groups and the times in the evaluation of ICP, and
vestibulomotor and motor function, the comparison of groups in each
time was analyzed using one-way analysis of variance (ANOVA), the
same as for an evaluation of the permeability of BBB and the brain
edema. Tukey's test was used for post hoc analysis. The signiﬁcant dif-
ference was accepted at p b 0.05.
3. Results
3.1. Brain edema: brain water content
The brain edemaof different groups is shown in Fig. 1. TBI resulted in
an increase in brain water content (79.3% ± 0.34) in comparison withFig. 1. The effect of genistein on the brain edema determined by the brain water content,
48 h post-severe traumatic brain injury (TBI) (n= 6 in each group). Data are presented as
mean±SEM. ***P b 0.001: TBI andVeh groups vs. shamgroup. ###P b 0.001:Gen group vs.
TBI group. $$$P b 0.001: Gen group vs. Veh group. Gen: genistein; Veh: vehicle.the sham group (77.1% ± 0.14), 48 h post-TBI (p b 0.001). Brain
edema was not signiﬁcantly different between TBI group and vehicle
group (79.51% ± 0.28). TBI-induced brain edema was reversed by
administration of genistein (77.12% ± 0.24) (p b 0.001). The brain
water content of genistein group was not signiﬁcantly different with
that of sham group.
3.2. BBB permeability: EB dye content of brain
BBB permeability of different groups is shown in Fig. 2. TBI increased
the brain content of EB dye (25.1 ± 3.6 μg/g tissue) in comparison with
sham group (3.7 ± 0.61 μg/g tissue), 48 h post-TBI (p b 0.001). The BBB
disruptionwas not signiﬁcantly different between TBI group and vehicle
group (23.7 ± 2.6 μg/g tissue). The administration of genistein reversed
(9.6 ± 1.8 μg/g tissue) TBI-induced BBB disruption (p b 0.01). The brain
content of EB dye in genistein groupwas not signiﬁcantly different with
that of sham group.
3.3. ICP
The ICP of different groups, before trauma, and on D0, D1 and D2
times after TBI, is shown in Fig. 3. Before trauma, ICPwas not statistically
different among the groups. TBI resulted in an increase of ICP on
D0 (7.16 ± 0.54 mm Hg), D1 (9.66 ± 0.49 mm Hg) and D2 (9.33 ±
0.61 mm Hg) times after TBI in comparison with sham group (3.16 ±
0.16, 2.83 ± 0.16, 3.5 ± 0.22 mm Hg; respectively) (p b 0.001). The
ICP of TBI group was not signiﬁcantly different with that of vehicle
group in any time. Although, genistein did not eliminate TBI-induced in-
crease of ICP on D0 and D1 (9± 0.85, 5.33± 0.61mmHg; respectively)
times but, eliminated that on D2 time (4.5 ± 0.5 mm Hg) (p b 0.001).
TBI-caused increase of ICP in the genistein group on D1 time was less
than that on Do time in comparison with the sham group. The ICP was
not signiﬁcantly different between the sham group and genistein
group on D2 time.
3.4. Neurobehavioral performance
3.4.1. Motor function of VCS
The motor performance in different groups, before trauma, and
on D0, D1 and D2 times, is shown in Fig. 4. Before trauma, the score
was not statistically different among the groups. TBI decreased motor
score on D0, D1 and D2 times (2 ± 0.36, 6.33 ± 0.33, 6.50 ± 0.42;Fig. 2. The effect of genistein on the permeability of blood–brain barrier determined by the
brain leakage of Evans blue dye, 48 h post-severe traumatic brain injury (TBI) (n = 6 in
each group). Data are presented as mean ± SEM. ***P b 0.001: TBI and Veh groups vs.
sham group. ##P b 0.01: Gen group vs. TBI group. $P b 0.05: Gen group vs. Veh group.
Gen: genistein; Veh: vehicle.
Fig. 3. The effect of genistein on the intracranial pressure, before trauma, on trauma day
(D0), and ﬁrst (D1) and second (D2) days post-severe traumatic brain injury (TBI)
(n = 6 in each group). Data are presented as mean ± SEM. ***P b 0.001: TBI and vehicle
groups vs. sham group on D0, D1 and D2 time; genistein group vs. sham group on
D0 time. ###P b 0.001: genistein group vs. TBI group on D1 and D2 times. $$$P b 0.001:
genistein group vs. vehicle group on D1 and D2 times. *P b 0.05: genistein group vs.
sham group on D1 time. Gen: genistein; Veh: vehicle.
Fig. 5. The effect of genistein (Gen) on the time (s) to traverse an elevated narrow beam,
before trauma, on trauma day (D0), and ﬁrst (D1) and second (D2) days post-severe trau-
matic brain injury (TBI) (n = 6 in each group). Data are presented as mean± SEM. ***P b
0.001: TBI group vs. sham group on D1 time. **P b 0.01: vehicle group vs. sham group on
D0, D1 and D2 times; TBI group vs. sham group onD2 time. ##P b 0.01: genistein group vs.
TBI group on D1 time.*P b 0.05: TBI and genistein groups vs. sham group on D0 time.
$P b 0.05: genistein group vs. vehicle group on D1 time. Gen: genistein; Veh: vehicle.
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with sham group (8± 0, 8± 0, 8± 0; respectively). Themotor score of
TBI group was not signiﬁcantly different with that of vehicle group in
any time. Although, genistein could not recover motor function on D0
time (1.67 ± 0.33) (p b 0.001) but, recovered motor function on D1
and D2 times (7.83 ± 0.16, 7.83 ± 0.16; respectively) in comparison
with TBI and vehicle groups (p b 0.01). The motor score was not signif-
icantly different between shamgroup and genistein grouponD1 andD2
times.
3.4.2. Vestibulomotor function: BW (traversal time)
The traversal time of BW task of different groups, before trauma, and
on D0, D1 and D2 times, is shown in Fig. 5. Before trauma, the timewasFig. 4. The effect of genistein on themotor function evaluated bymotor score of veterinary
coma scale, before trauma, on trauma day (D0), and ﬁrst (D1) and second (D2) days post-
severe traumatic brain injury (TBI) (n = 6 in each group). Data are presented as mean ±
SEM. ***P b 0.001: TBI, vehicle and genistein groups vs. sham group onD0 time. **P b 0.01:
TBI and vehicle groups vs. sham group on D1 and D2 times. ##P b 0.01: genistein group vs.
TBI group on D1 and D2 times. $$P b 0.01: genistein group vs. vehicle group on D1 and D2
times. Gen: genistein; Veh: vehicle.not statistically different among the groups as, all rats reached the goal
box in approximately 5 s. TBI increased traversal time in all times after
trauma (11.55 ± 1.35, 11.38 ± 0.81, 10.27 ± 0.68 s; respectively) in
comparison with sham group (6.27 ± 0.62, 5.66 ± 0.32, 4.88 ±
0.18 s; respectively) (p b 0.05, p b 0.001, p b 0.01; respectively). There
was no signiﬁcant difference between TBI group and vehicle group in
any time. Although, genistein could not reduce traversal time on D0
time (10.88 ± 0.95 s) but, reduced traversal time on D1 and D2 times
(6.55 ± 0.48, 7.27 ± 0.39 s; respectively). The motor score of genistein
groupwas not signiﬁcantly differentwith that of sham group on D1 and
D2 times.
3.4.3. Vestibulomotor function: BW (distance traveled)
The score of distance traveled in BW task of different groups, before
trauma, and on D0, D1 and D2 times, is shown in Fig. 6. Before trauma,Fig. 6. The effect of genistein on the distance traveled score along an elevated narrow
beam, before trauma, on trauma day (D0), and ﬁrst (D1) and second (D2) days post-
severe traumatic brain injury (TBI) (n = 6 in each group). Data are presented as
mean ± SEM. *P b 0.05: Veh and TBI groups vs. sham group on D0 time. Gen: genistein;
Veh: vehicle.
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groups as, all rats traversed an entire length of beam for a maximum
score of 5. A reduction of the score was showed in TBI and vehicle
groups in comparison with sham group, only on D0 time. There was
no signiﬁcant difference between sham group and genistein group on
D0 time. There was no signiﬁcant difference among groups on D1 and
D2 times.
4. Discussion
In the present study, for the ﬁrst time, the neuroprotective effect
of genistein, as a soy isoﬂavone was evaluated in an animal model of
diffuse TBI. In this survey, the administration of genistein reduced
brain edema, BBB permeability and ICP, and improved the disturbance
of neurobehavioral performance in TBI animals.
Although it is known that 17β-estradiol has the neuroprotective
effect in brain injuries [7,8,31], but the usage of estrogen increases a
risk of breast cancer. Phytoestrogens have been introduced as an alter-
native to hormonal replacement therapy, because phytoestrogens
have the estrogenic-like effects without a risk of breast cancer. Phyto-
estrogens are natural molecules derived from plants that can act as an
estrogen receptor agonist [15] or an antagonist [32] in the nervous sys-
tem. Phytoestrogens are found in someproducts, such as soy [33]which
contains genistein and daidzein among other isoﬂavones [34]. The
structure of soy isoﬂavones (genistein, daidzein, glycitein), is similar
to endogenous estrogens. It is known that isoﬂavones act as an estrogen
receptor modulator or act through a non-estrogen receptor pathway
[13,35].
A damage in the central nervous system results in neuro-
inﬂammatory responses including, the formation of brain edema, the
disruption of BBB [36], the elevation of ICP [8] and the acute increase
of pro-inﬂammatory cytokines [9].
Studies have shown that the brain water content and the content of
Evans blue dye in the brain following TBI are signiﬁcantly high in com-
parison with control group, 48 h post-trauma [37,38], in accordance
with our present ﬁndings. Administration of genistein resulted in
inhibiting the brain edema development and the BBB disruption. The
effect of genistein on the disruption of BBB in this study is in agreement
with the report of protection of the BBB after cerebral ischemia in soy-
fed animals [21,39]. Also, an antiedema effect of isoﬂavones in cerebral
ischemia/reperfusion [26,40] agrees with an antiedema effect of genis-
tein in this study. Ma et al. showed that a protective effect of soy on
the permeability of BBB is mediated by a reduction of endothelial
hypoxia-inducible factor 1-alpha (HIF1-α) and vascular endothelial
growth factor (VEGF) [39]. It is known that an elevation of free radicals
[41] and a development of inﬂammatory mechanisms [41,42] have a
role in the BBB disruption and the brain edema development. The scav-
enging [26] and antiinﬂammatory effects of genistein [43] have been
demonstrated. Therefore it is proposed that the inhibitory effects of ge-
nistein in the development of brain edema and the disruption of BBB
probably are mediated via antioxidant and antiinﬂammatory effects as
well as vascular protective alterations.
An increase of ICP for 48 h post-TBI has been reported in other
studies [27,44] that is a conﬁrmation for a time course of the increase
of ICP in the present study. We showed that an increase of ICP was ini-
tiated in the ﬁrst hour of trauma, and persisted for 48 h. Our present
research indicated that genistein could not eliminate an increase of
ICP on the trauma day (ﬁrst hour). Although genistein weakened an
increase of ICP on the ﬁrst day of post-trauma, but inhibited that on
the second day of post-trauma, as the level of ICP was not different
between genistein group and sham group in this time. The reasons of
an increase of ICP in TBI could be hypoxia [45], a reduction of cerebral
blood ﬂow [46], cerebral edema [47], ischemic injury, a hyperperfusion
in the early stages after TBI [48], and changes in the expression of
aquaporin-4 [49]. Our recent study reported a reduction of ICP along a
reduction of vasogenic edema following TBI by dietary soy as is seenin present research [21]. Therefore it is supposed that genistein may
decrease ICP following a decrease in brain edema. Estrogen prevents
increasing ICP post-TBI by its antioxidant effect [50]. Since, soy
isoﬂavones have an antioxidant effect [51], this effect is also deemed
as another action mechanism of genistein in suppressing an increase
of ICP. Since genistein did not castrate an increase of ICP on the day of
trauma but castrated that on days post-trauma, it seems that action
mechanism of genistein on ICP may be mediated by a decrease in brain
edema than an antioxidant effect, although it is needed to research for
conﬁrmation.
The neurobehavioral performance was evaluated by assessing a
motor function using VCS test and a vestibulomotor function using a
BW test. In our research, a deterioration ofmotor functionwas observed
on trauma day, and persisted along 48 h post-trauma, in agreement
with the results of other studies [37,44]. In evaluating a vestibulomotor
function, we observed that the traversal time increased on trauma day,
and continued until 48 h post-trauma, whereas the score of distance
reduced only on the trauma day, which is inconsistent with the result
of research performed in ratswith diffuse TBI [52].Weobserved that ge-
nistein could not improve motor and vestibulomotor function on the
day of trauma, but improved that on the days post-trauma, in accor-
dancewith an effect of genistein on ICP. The improvement of neurologic
function by genistein has been reported in a model of experimental
ischemia [53]. The dietary soy improved the neurobehavioral function
in male rats following TBI [21]. The brain edema is a prime cause of a
deterioration of neurobehavioral function following TBI [54]. The im-
provement of neurologic function can occur following a decrease in
ICP in a brain injury [27,29]. It is assumed that the decrease in ICP may
be an action mechanism of soy in the improvement of neurobehavioral
performance. The improvement in neurobehavioral function correlates
with the signiﬁcant cortical and hippocampal tissue preservation [43].
A reduction of brain lesion by genistein administration has been indicat-
ed in a model of experimental stroke [19], but this must be assessed
in our future research. The beneﬁcial effect of genistein on neurobehav-
ioral performance has not been reported in some studies [24,55] and
in the rat brain in vitro [25]. The methodological, strain, sex, dose of
consumption of genistein, and brain injury differences can be causes
of the discrepancies.
Studies suggest that the neuroprotective effects of genistein are at
least in part, mediated by estrogen receptors [56,57]. Although, soy
isoﬂavones may activate both estrogen receptor α and estrogen recep-
tor β, they activate more estrogen receptor β [58], which is highly
expressed in neurons and glial cells in the hippocampal formation
[59]. Estrogen receptor-independent neuroprotection of genistein can
exist via altering the activity of enzymes, such as protein tyrosine
kinases leading to affecting the activity of neurotransmitter receptors
[60], DNA topoisomerase I and II, and ribosomal S6 kinase [61,62], via
a direct interaction with neurotransmitter receptors [63], and ﬁnally
via the antioxidant properties [22].
The probable cellular and molecular mechanisms of genistein as
a neuroprotective factor can be as follows: the reduction of neuronal
apoptosis [24], oxidative stress [22], glutamate excitotoxicity [23], the
activation of PI3K [60] of [15], and β-amyloid protein. The molecular
and additional mechanisms underlying the beneﬁcial effect of genistein
in TBI are a subject of future research. It must also be determined
whether the effects of genistein are performed via estrogen receptors
and also which of the estrogen receptor is involved.
The results of this study suggest that at least in part a preventive ef-
fect of dietary soy ismediated via an isoﬂavone ingredient; i.e. genistein
that needs further research and conﬁrmation. The comparison effect of
dietary soy to genistein, also a combination of dietary soy and genistein
is subject of future research.
We indicated that administration of genistein reduces brain edema,
BBB permeability, and ICP and also improves motor and vestibulomotor
deﬁcits in TBI. These ﬁndings support that genistein can be considered
as a neuroprotective agent and a possible alternative to estrogen.
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